Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 USD | +1.47% | -8.99% | -63.05% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 282M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.04
x | P/E ratio 2025 * |
-3.95
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +1.47% | ||
1 week | -8.99% | ||
Current month | -32.42% | ||
1 month | -32.42% | ||
3 months | -45.66% | ||
6 months | -33.85% | ||
Current year | -63.05% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.44 | +1.47% | 949,972 |
24-04-25 | 3.39 | -0.59% | 1,272,866 |
24-04-24 | 3.41 | -7.34% | 1,955,839 |
24-04-23 | 3.68 | 0.00% | 1,365,920 |
24-04-22 | 3.68 | -2.65% | 1,358,524 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.05% | 282M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AVXL Stock